Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of phase ii quack trial

HIGHLIGHTS

• who: Akira Ooki from the Department of Gastroenterological Chemotherapy, Institute Tokyo, u20118550, Japan have published the research work: Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial, in the Journal: (JOURNAL) of July/19,/2013
• what: The aim of this study was to assess the association of ETS with HRQOL and prognostic outcomes according to the baseline symptom status by performing a post hoc analysis of the QUACK trial data.
• future: Future studies . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.